↓ Skip to main content

Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial)

Overview of attention for article published in BMC Cancer, December 2021
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
23 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial)
Published in
BMC Cancer, December 2021
DOI 10.1186/s12885-021-08990-3
Pubmed ID
Authors

Nieves Martinez Chanza, Louisa Soukane, Philippe Barthelemy, Aurélien Carnot, Thierry Gil, Vinciane Casert, Vincent Vanhaudenarde, Brieuc Sautois, Lionel Staudacher, Jan Van den Brande, Stephane Culine, Emmanuel Seront, Marco Gizzi, Simone Albisinni, Thibault Tricard, Jean Christophe Fantoni, Marianne Paesmans, Rafael Caparica, Thierry Roumeguere, Ahmad Awada

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 23 100%

Demographic breakdown

Readers by professional status Count As %
Student > Postgraduate 3 13%
Student > Doctoral Student 2 9%
Student > Bachelor 2 9%
Researcher 2 9%
Professor > Associate Professor 1 4%
Other 1 4%
Unknown 12 52%
Readers by discipline Count As %
Medicine and Dentistry 7 30%
Biochemistry, Genetics and Molecular Biology 2 9%
Pharmacology, Toxicology and Pharmaceutical Science 1 4%
Engineering 1 4%
Unknown 12 52%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 December 2021.
All research outputs
#20,147,309
of 22,653,392 outputs
Outputs from BMC Cancer
#6,476
of 8,237 outputs
Outputs of similar age
#405,111
of 496,583 outputs
Outputs of similar age from BMC Cancer
#153
of 228 outputs
Altmetric has tracked 22,653,392 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,237 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 496,583 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 228 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.